Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers

Methods in Molecular Biology

Volumn 867, Issue , 2012, Pages 143-167

  Popplewell, Linda J ^a   Malerba, Alberto ^a   Dickson, George ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antisense oligonucleotides; DMD; Exon skipping; Functional analysis; Optimization; Phosphorodiamidate morpholino oligomers

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DNA; DYSTROPHIN; MORPHOLINO OLIGONUCLEOTIDE; RNA;

AGAR GEL ELECTROPHORESIS; ANIMAL; ARTICLE; CELL CULTURE; CYTOLOGY; DUCHENNE MUSCULAR DYSTROPHY; EXON; GENETIC TRANSFECTION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; NUCLEIC ACID HYBRIDIZATION; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; SKELETAL MUSCLE;

ANIMALS; CELLS, CULTURED; DNA; DYSTROPHIN; ELECTROPHORESIS, AGAR GEL; EXONS; HUMANS; MORPHOLINOS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDES, ANTISENSE; READING FRAMES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA SPLICING; TRANSFECTION;

ANIMALIA;

EID: 84859812797     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-767-5_10     Document Type: Article

References (28)

1. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM (1988) An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2:90-95
2. Bertoni C (2008) Clinical approaches in the treatment of Duchenne muscular dystrophy (DMD) using oligonucleotides. Front Biosci 13:517-527 (Pubitemid 351599762)
3. Trollet C, Athanasopoulos T, Popplewell L, Malerba A, Dickson G (2009) Gene therapy for muscular dystrophy: current progress and future prospects. Expert Opin Biol Ther 9: 849-866
4. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, Den Dennen JT, Baas F et al (2003) Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 12:907-914 (Pubitemid 36504033)
5. van Deutekom JC, Bremmer-Bout M, Janson AA, Ginjaar IB, Baas F, den Dunnen JT et al (2001) Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet 10: 1547-1554 (Pubitemid 32734306)
6. Arechavala-Gomeza V, Graham IR, Popplewell LJ, Adams AM, Aartsma-Rus A, Kinali M et al (2007) Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther 18: 798-810 (Pubitemid 47502846)
7. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, den Dunnen JT, Baas F et al (2003) Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 12: 907-914 (Pubitemid 36504033)
8. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, van Ommen GJ, den Dunnen JT et al (2004) Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet 74:83-92 (Pubitemid 38085240)
9. Aartsma-Rus A, Janson AA, van Ommen GJ, van Deutekom JCT (2007) Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy. BMC Med Genet 8: 43-51
10. Bremmer-Bout M, Aartsma-Rus A, de Meijer EJ, Kaman WE, Janson AA, Vossen RH et al (2004) Targeted exon skipping in transgenic hDMD mice: a model for direct preclinical screening of human-specific antisense oligonucleotides. Mol Ther 10:232-240 (Pubitemid 39117869)
11. Graham IR, Hill VJ, Manoharan M, Inamati GB, Dickson G (2004) Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays. J Gene Med 6:1149-1158 (Pubitemid 40228127)
12. Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J et al (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 102:198-203 (Pubitemid 40094452)
13. Mann CJ, Honeyman K, Cheng AJ, Ly T, Lloyd F, Fletcher S et al (2001) Antisenseinduced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA 98:42-47 (Pubitemid 32095860)
14. Jearawiriyapaisarn N, Moulton HM, Buckley B, Roberts J, Sazani P, Fucharoen S et al (2008) Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 16: 1624-1629
15. van Deutekom JC, Janson AA, Ginjaar IB, Franzhuzen WS, Aartsma-Rus A, Bremmer-Bout M et al (2007) Local antisense dystrophin restoration with antisense oligonucleotide PRO051. N Eng J Med 357:2677-2687
16. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C et al (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebocontrolled, dose-escalation, proof-of-concept study. Lancet Neurol 8(10):918-928
17. Arora V, Devi GR, Iversen PL (2004) Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics. Curr Pharm Biotechnol 5:431-439 (Pubitemid 39317610)
18. Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg GJ et al (2009) In vivo comparison of 2'O-methyl-PS and morpholino antisense oligonucleotides for DMD exon skipping. J Gene Med 11:257-266
19. Gebski BL, Mann CJ, Fletcher S, Wilton SD (2003) Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum Mol Genet 12:1801-1811 (Pubitemid 36944135)
20. Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD et al (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12:175-177 (Pubitemid 43214742)
21. Malerba A, Thorogood FC, Dickson G, Graham IR (2009) Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice. Hum Gene Ther 20(9):955-965
22. McClorey G, Fall AM, Moulton HM, Iversen PL, Rasko JE, Ryan M et al (2006) Induced dystrophin exon skipping in human muscle explants. Neuromuscul Disord 16:583-590 (Pubitemid 44374319)
23. McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD (2006) Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 13:1373-1381 (Pubitemid 44420632)
24. Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ et al (2009) Theoretic applicability of antisensemediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 30:292-299
25. Aartsma-Rus A, De Winter CL, Janson AAM, Kaman WE, van Ommen G-JB, Den Dunnen JT et al (2005) Functional analysis of 114 exoninternal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites. Oligonucleotides 15: 284-297 (Pubitemid 43108225)
26. Wilton SD, Fall AM, Harding PL, McClorey G, Coleman C, Fletcher S (2007) Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol Ther 15:1288-1296 (Pubitemid 46965325)
27. Aartsma-Rus A, van Vliet L, Hirschi M, Janson AA, Heemskerk H, de Winter CL et al (2009) Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Mol Ther 17:548-553
28. Popplewell LJ, Trollet C, Dickson G, Graham IR (2009) Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene. Mol Ther 17:554-561